Definium Therapeutics
The Executive Director, Expanded Access & Phase 4 Clinical Strategy will lead the end-to-end strategy, design, and execution of Expanded Access Programs and Phase 4 studies across MindMed’s portfolio. This role ensures programs are scientifically sound, operationally feasible, regulator-ready, and aligned with asset lifecycle, real-world evidence generation, and post-approval commitments. The position requires strategic leadership combined with hands-on execution and cross-functional collaboration across clinical, regulatory, medical affairs, and commercial teams.
Headquarters
New York, New York, United States
Company Size
51-200 employees
Founded
2019
Definium Therapeutics (formerly MindMed) is a clinical-stage biopharmaceutical company forging a new era in psychiatry by harnessing the therapeutic potential of psychedelic medicine. The company develops proprietary treatments including DT120 ODT, a pharmaceutically optimized formulation of lysergide (LSD), and DT402, the R-enantiomer of MDMA, targeting brain health disorders such as generalized anxiety disorder, major depressive disorder, PTSD, and autism spectrum disorder. Guided by precision science and clinical rigor, Definium Therapeutics aims to deliver accessible, scalable treatments that address the root causes of mental health conditions.
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
Jan 12, 2026
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) high institutional ownership speaks for itself as stock continues to impress, up 26% over last week
Sep 30, 2025
Mind Medicine Readies for Data-Rich 2026 Pivot
5 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Definium Therapeutics.
Mind Medicine (MindMed) (NASDAQ:MNMD) Hits New 12-Month High - Should You Buy?
Sep 29, 2025
Executive Director, Late Stage Clinical Strategy
Definium Therapeutics
Senior Clinical Trial Manager, Research Alliances
Iovance Biotherapeutics
Medical Director Endocrinology Europe, MD
Neurocrine Biosciences
Clinical Development, Program Lead
altoneuroscience
Executive Medical Director, Clinical Development, Neurodegeneration
Neurocrine Biosciences
Executive Director, Medical Director, Psychiatry - Basel
Neurocrine Biosciences